Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).

Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

Abstract: The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.

Abstract: The invention provides for an enteral nutritional composition comprising (a) a lipid fraction, (b) a digestible carbohydrate fraction and (c) a protein fraction, wherein the lipid fraction comprises therapeutically effective amounts of (i) DHA and optionally EPA, and (ii) medium-chain triglycerides, preferably at least 2 wt % C8 and C10 medium-chain triglycerides based on weight of the fatty acids; and wherein the composition has a ketogenic weight ratio between 1.4:1 and 3:1, for use in the treatment of traumatic brain injury (TBI).

Abstract: The invention pertains to a composition for use in (a) treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease; and/or (c) reducing L-DOPA associated side effects, preferably involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, comprising co-administering to the subject L-DOPA and a composition comprising therapeutically effective amounts of: (i) at least one of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof; (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA); (iii) choline, or salts or esters thereof; and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.

Abstract: The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

Abstract: The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

Abstract: The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white matter lesions, white matter hyperintensities (WMH), Leukoaraiosis or periventricular white matter disease in elderly not suffering from a neurodegenerative disorder, preferably non-demented elderly and elderly not suffering from Alzheimer's Disease. It was found that with the compositions according to the invention Nogo-A protein levels could be controlled, particularly suppressed or reduced.

Abstract: The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.